Despite marked improvements in the prognosis of HER-2 positive breast cancers, which have been observed due to the widespread use of HER-2-specific therapies, such as trastuzumab, patients continue to exhibit recurrences and disease progression (6). Here, ERBB2 is linked to breast carcinoma.